Rong

Our @natbiotech.nature.com editorial team picks our favorite research articles from 2025. We’ve also posted a Chinese version here 👉 mp.weixin.qq.com/s/fY10zwuljH...

The brief digital edition of Nature Biotechnology November issue is live now! 🎉 Check it out here👉 mp.weixin.qq.com/s/RxFGoMOwgv... @natbiotech.nature.com

Looking forward to #SITC25 next week! Please get in touch if you’d like to discuss your upcoming submissions to Nature Biotechnology! @natbiotech.nature.com

New online in @natbiotech.nature.com : The interactions of CAT-T cells and solid tumors are modeled on a chip.

The brief digital edition of our Nature Biotechnology October issue is live now! 🎉 Check it out here: mp.weixin.qq.com/s/nZSLSSxF4s... @natbiotech.nature.com

The brief digital edition of our @natbiotech.nature.com September issue is live now! Check it out here: mp.weixin.qq.com/s/vDXak-Ph4k...

Wearables Roundtable: Bao and Rogers | Forum

On our latest podcast, Barbara Cheifet talks with Zhenan Bao and John Rogers about the latest in electronic wearables and how they will complement and advance global health — from health monitoring in neonates to smart bandages for wounds shows.acast.com/forum/episod...

Stereo-cell: Spatial enhanced-resolution single-cell sequencing with high-density DNA nanoball-patterned arrays Single-cell sequencing technologies have advanced our understanding of cellular heterogeneity and biological complexity. However, existing methods face limitations in throughput, capture uniformity, c...

Stereo-cell is a DNA nanoball array-based method that enables scalable, spatially resolved single-cell sequencing across diverse cell types and sizes with multimodal integration capabilities. #NBThighlight www.science.org/doi/10.1126/...

The brief digital edition of our @natbiotech.nature.com August issue is live now! Check it out here: mp.weixin.qq.com/s/ZIDiPktIya...

The brief digital edition of our June issue is live now! Check it out here: mp.weixin.qq.com/s/S9nAe_uF0Z...

In vivo CAR T cell generation to treat cancer and autoimmune disease Chimeric antigen receptor (CAR) T cell therapies have transformed treatment of B cell malignancies. However, their broader application is limited by complex manufacturing processes and the necessity f...

CD8-targeted lipid nanoparticles carrying anti-CD19 CAR mRNA were developed to generate CAR-T cells directly in vivo, demonstrating effective B cell depletion for potential treatment of B cell malignancies and autoimmune diseases. www.science.org/doi/10.1126/... #NBThighlight

The brief digital edition of our May issue is live now! Check it out here: mp.weixin.qq.com/s/Ph75nRcl02...

Baby Is Healed With World’s First Personalized Gene-Editing Treatment

A gene-editing treatment used on a 9½-month-old boy with a rare condition has the potential to help people with thousands of other uncommon genetic diseases #NBTNewsBeat www.nytimes.com/2025/05/15/h...

Five questions with Jie Sun - Nature Biotechnology This developer of cancer immunotherapies discusses her early fascination with cellular behavior, perseverance and deep desire to directly impact patient care.

This developer of cancer immunotherapies discusses her early fascination with cellular behavior, perseverance and deep desire to directly impact patient care go.nature.com/3RSlwqL
rdcu.be/ej8IO

Cancer vaccines: the experts speak - Nature Biotechnology The development of therapeutic cancer vaccines has long been a promising yet challenging field of research. While early efforts were impeded by limited efficacy and immune escape, recent advances in i...

Cancer vaccines: the experts speak www.nature.com/articles/s41...

Synergizing advances in artificial intelligence with mathematical modeling will improve our ability to computationally predict immunotherapy outcomes go.nature.com/4jfqM3Y
rdcu.be/eh1qR

Making cell therapy accessible: challenges and opportunities - Nature Biotechnology Despite major advances in bringing cancer cell therapies to the clinic, their widespread accessibility remains a substantial challenge. High manufacturing costs, lack of funding and varying regulatory...

Cell therapies are transforming our ability to treat cancer but are out of reach for many patients. We asked experts to share their insights into the challenges and strategies to make these therapies more broadly accessible go.nature.com/3YCJn1o
rdcu.be/eiaZ4

Turn cold tumors hot by reprogramming the tumor microenvironment - Nature Biotechnology The identification of novel targets together with technological advances is transforming our ability to effectively modulate the tumor microenvironment.

The identification of novel targets together with technological advances is transforming our ability to effectively modulate the tumor microenvironment go.nature.com/42Bo9lT
rdcu.be/eiiow

The brief digital edition of our 2025 Cancer Immunotherapy Focus Issue is live as well! Check it out here: mp.weixin.qq.com/s/i5t1sfgpL-...

Making cell therapy accessible: challenges and opportunities - Nature Biotechnology Despite major advances in bringing cancer cell therapies to the clinic, their widespread accessibility remains a substantial challenge. High manufacturing costs, lack of funding and varying regulatory...

Cell therapies are transforming our ability to treat cancer but are out of reach for many patients. @natbiotech.nature.com asked experts to share their insights into pressing challenges and promising strategies to make these therapies more broadly accessible www.nature.com/articles/s41...

Engineering innate immune cells for cancer immunotherapy - Nature Biotechnology The unique attributes of innate immune cells position them as attractive candidates for cancer immunotherapy, with engineering strategies to enhance their antitumor potential, offering notable therape...

Innate immune cells are promising candidates for cancer immunotherapy and various engineering strategies can be employed to set them up for success. Read about is in this Review in @natbiotech.nature.com and don't forget to check out our full Focus Issue! www.nature.com/articles/s41...

This month, we've focused on recent developments as well as challenges in cancer immunotherapy, including cancer vaccines, immune checkpoint inhibitors, and CAR-engineered cells. Please read more👇

Our 2025 Focus issue on Cancer Immunotherapy is live now! More details below

⭐ I'm hiring a new Chief editor for Nature Biomedical engineering, in New York, Beijing or Shanghai.

Please apply here: springernature.wd3.myworkdayjobs.com/SpringerNatu...

Engineering sonogenetic EchoBack-CAR T cells Sonogenetic EchoBack-CAR T cells were designed with an ultrasensitive heat-shock promoter screened from a library and a synthetic positive feedback loop that reprograms tumor engagement into CAR T cel...

Sonogenetic EchoBack-CAR T cells incorporate an ultrasensitive heat-shock promoter and synthetic positive feedback loop, enabling focused-ultrasound-controlled long-lasting CAR expression and enhanced anti-tumor efficacy. www.cell.com/cell/fulltex... #NBThighlight

An open letter to graduate students and other procrastinators: it’s time to write - Nature Biotechnology Nature Biotechnology - An open letter to graduate students and other procrastinators: it’s time to write

Writing is the most essential activity of a scientist because without writing there is no thinking and no real opportunity for exchange in the marketplace of ideas go.nature.com/4iXlwRQ
rdcu.be/ee4X5

2H24 biotech job picture go.nature.com/42hUCgY

The lasso peptide lariocidin functions as a broad-spectrum antibiotic by binding to a unique site on the bacterial ribosome, disrupting protein synthesis without affecting human cells, and demonstrating low potential for resistance development. www.nature.com/articles/s41... #NBThighlight

The brief digital edition of our March issue is live as well! Check it out here mp.weixin.qq.com/s/5MDvA1JHC0...

New online in @naturebiotech.bsky.social: Lipid nanoparticles carrying plasmid DNA and an inflammation inhibitor enable longer transgene expression than mRNA nanoparticles-by Manthan N. Patel, Jacob S. Brenner et al.